Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surgical Excision vs Curettage plus Imiquimod for Nodular Basal Cell Carcinoma
2014-003479-52Phase 3Completed
- Sponsor
- Maastricht University Medical Center+
- Start
- Sep 2014
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imiquimod in basal cell carcinoma (BCC) (2 arms), sponsored by Maastricht University Medical Center+. Primary endpoint: Proportion of patients free of initial nBCC at 1 year. Started Sep 2014; status: completed.
02
Drugs
imiquimod
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2014-003479-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003479-52.